1. SHP2 and UGP2 are Biomarkers for Progression and Poor Prognosis of Gallbladder Cancer.
- Author
-
Wang, Qunwei, Yang, Zhu-lin, Zou, Qiong, Yuan, Yuan, Li, Jinghe, Liang, Lufeng, Zeng, Guixiang, and Chen, Senlin
- Subjects
- *
GALLBLADDER cancer , *CANCER diagnosis , *CANCER prognosis , *CANCER treatment , *CANCER genetics , *BIOMARKERS , *CANCER invasiveness , *ANTHROPOMETRY , *ESTERASES , *IMMUNOHISTOCHEMISTRY , *GALLBLADDER tumors , *METASTASIS , *PROGNOSIS , *TRANSFERASES , *TUMOR classification , *DISEASE progression , *KAPLAN-Meier estimator , *TUMOR grading , *DIAGNOSIS , *TUMOR treatment - Abstract
Biomarkers for the diagnosis, prognosis, and targeting therapy of gallbladder cancers are not clinically available. This study demonstrated that the percentage of cases with positive SHP2 and UGP2 expression significantly correlated with the percentage of cases with positive vimentin, β-catenin, MMP2, MMP9, and Ki-67 expression, large tumor size, high TNM stage, lymph node metastasis, and survival in patients with adenocarcinomas and squamous cell/adenosquamous carcinomas. Positive SHP2 and UGP2 expression are independent poor-prognostic factors in both types of tumors. Our study suggested that positive SHP2 and UGP2 expression correlated with clinicopathological and biological behaviors, and poor-prognosis of gallbladder cancer. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF